Ignite Creation Date:
2025-12-25 @ 1:34 AM
Ignite Modification Date:
2025-12-29 @ 7:40 PM
Study NCT ID:
NCT00519194
Status:
TERMINATED
Last Update Posted:
2019-02-19
First Post:
2007-08-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Sponsor:
Abbott Medical Devices
Organization:
Study Overview
Official Title:
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Status:
TERMINATED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CONVERT-AF
Brief Summary:
The purpose of this study is to test the safety and efficacy of the Epicor LP Cardiac Ablation System for treating permanent atrial fibrillation during concomitant open chest and/or open heart surgery for one of more of the following procedures: mitral valve repair or replacement, aortic valve repair or replacement, tricuspid valve repair or replacement, coronary artery bypass surgery or patent foramen ovale (PFO closure).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: